Workflow
Sunrun Reports Fourth Quarter and Full Year 2025 Financial Results
Globenewswire· 2026-02-26 21:01
Net change in cash and restricted cash of $290 million and Cash Generation1 of $377 million in 2025 Outlook for positive Cash Generation2 in the range of $250 million to $450 million for full year 2026 Aggregate Subscriber Value of $1.3 billion in Q4 Contracted Net Value Creation of $176 million in Q4, or $0.76 per share Storage Attachment Rate reached record 71% in Q4 Paid down $81 million of recourse debt in Q4 with excess cash SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), America ...
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
Globenewswire· 2026-02-26 21:01
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. “2025 was a year of disciplined execution for P ...
Keros Therapeutics Appoints Charles Newton to its Board of Directors
Globenewswire· 2026-02-26 21:01
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. “We are pleased to welcom ...
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Globenewswire· 2026-02-26 21:01
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain Pro forma cash of $716 million including recent ATM sales extends cash runway into second half of 2027Xen ...
Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics
Globenewswire· 2026-02-26 21:01
Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDARaises health plan membership guidance by 2,000 at the midpoint and introduces 2026 revenue guidance of $5.14 billion to $5.19 billion, representing 30%-31% growth year-over-year, and adjusted EBITDA of $133 million to $163 millionEarns recognition on the 2026 Fortune World’s Most ...
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
Globenewswire· 2026-02-26 21:01
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. “In 2025, we were able to retur ...
Progyny, Inc. Announces Fourth Quarter 2025 Results
Globenewswire· 2026-02-26 21:01
Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health an ...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences 
Globenewswire· 2026-02-26 21:01
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/26 Intereste ...
Compass and Rocket Form Historic Alliance to Dramatically Increase Home Listing Inventory on Redfin
Prnewswire· 2026-02-26 21:01
Compass and Rocket Form Historic Alliance to Dramatically Increase Home Listing Inventory on Redfin [Accessibility Statement] Skip Navigation--Rocket Companies, Inc. logo (PRNewsfoto/Rocket Companies)Compass International Holdings logo- Integrated search, agent and mortgage experience designed to make the homebuying process straightforward with less friction.- Compass International Holdings' unique inventory to appear on Redfin.com, with the potential to bring more than 500,000 additional home listings to m ...
Duolingo Reports Fourth Quarter and Full Year 2025 Results
Globenewswire· 2026-02-26 21:01
PITTSBURGH, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Duolingo, Inc. (NASDAQ: DUOL) announced results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted on its Investor Relations website at investors.duolingo.com. “We closed 2025 with strong momentum, surpassing 50 million daily active users and generating more than $1 billion in bookings for the first time,” said Luis von Ahn, Co-Founder and CEO of Duolingo. “At the same time, advances in AI are fundamentally reshap ...